An Open Label Trial of Azithromycin in Chronic Productive Cough

Chronic Cough Clinical Trial

— AZCC  

Official title:

An Open Label Trial of Azithromycin in Chronic Productive Cough

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02196493
• Other study ID #: 13031
• Secondary ID: 2013-002938-20
• Status: Recruiting
• Phase: Phase 3
• First received: July 10, 2014
• Last updated: February 17, 2016
• Start date: December 2013
• Est. completion date: December 2016

Study information

• Verified date: February 2016
• Source: University of Nottingham
• Contact: Matthew Martin, MBChB
• Phone: 01158231935
• Email: matthew.martin[@]nottingham.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

We have noticed a group of patients presenting with a longstanding wet cough which has often been treated as asthma. The cough is productive of sputum which frequently contains bacteria, but does not resolve with standard antibiotic treatment.

A very similar cough is seen in subjects who smoke, have exposure to airbourne dusts or chemicals or have a condition known as bronchiectasis, but these problems have already been excluded.

We have found that prolonged treatment with an antibiotic called azithromycin is very effective but using azithromycin in this way is not licensed and there is currently no trial evidence to support its use.

This research will evaluate the clinical benefit of low dose azithromycin to determine if this is an effective and safe treatment for these patients. It will also involve a detailed investigation of these patients to determine whether they have enough in common to believe we are describing a new condition.

Description:

We and others have observed a cohort of patients, mainly referred with either poorly controlled asthma despite high dose treatment or suspected bronchiectasis, who give a history of chronic (often 3 months or more) productive cough which improves with antibiotic treatment but quickly relapses. Most deny wheeze and on examination there are often transmitted sounds from mucus in the large airways but no expiratory wheeze typical of asthma. Investigations including spirometry, bronchial challenges, chest X-ray, screen for immunodeficiency and high resolution CT (HRCT) scan exclude recognised causes of productive cough but sputum culture is often positive for Haemophilus influenzae although sometimes demonstrates normal respiratory flora despite being markedly purulent.

Due to their efficacy in cystic fibrosis and bronchiectasis we have empirically tried treatment with low dose macrolide antibiotics over 3-6 months often with dramatic benefit. This is however an unproven and unlicensed indication which needs to be more thoroughly evaluated.

The key objective of the study is to determine if 12 weeks treatment of patients with chronic productive cough with low dose azithromycin is both effective and safe.

The secondary objectives of the study are to describe the clinical and pathological features of a cohort of patients who present with chronic productive cough (with no evidence of bronchiectasis, smoking-related chronic bronchitis or immunodeficiency) to determine if these are sufficiently similar to justify a new diagnostic label.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18 and over

• Male or female

• Non-smokers for 10 years and <20 pack year equivalents in total

• Persistent productive cough for > 3 months in duration

• Use of effective contraception Acceptable contraceptive methods include: established use of oral, injected or implanted hormonal methods; placement of an intrauterine device (IUD) or intrauterine system (IUS); condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide; true abstinence (when this is in line with the preferred and usual lifestyle of the participant); or vasectomised partner.

Exclusion Criteria:

• History of obvious inhaled irritant exposure

• Evidence of primary or secondary immunodeficiency.

• Clinically important bronchiectasis on HRCT scan

• Prolonged QT interval on ECG or significant cardiac pathology prior to commencing azithromycin

• Abnormal LFT's (greater than 2x upper limit of normal)

• Hypersensitivity to azithromycin or any macrolide/ketolide antibiotic

• Pregnancy or intent to become pregnant during course of study

• Contra-indication to bronchoscopy (as per British Thoracic Society Guidelines)

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Cough
• Cough

Intervention

Drug:
• Azithromycin
250mg azithromycin three times per week for 12 weeks

Locations

Country	Name	City	State
United Kingdom	Respiratory Research Unit	Nottingham	Nottinghamshire

Sponsors (1)

Lead Sponsor	Collaborator
University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in cough on the Leicester Cough Questionnaire (LCQ) score at week 12		12 weeks after treatment started	No
Secondary	Change from baseline in sputum colour (as per previously validated commercially available graded sputum colour chart) at week 12		12 weeks after treatment started	No
Secondary	Change from baseline in exhaled nitric oxide level (ppm) at week 24		12 weeks after treatment started	No
Secondary	Change from baseline in FEV1 (ml) at week 24		12 weeks after treatment started	No
Secondary	Change from baseline in sputum volume (ml) at week 12		12 weeks after treatment started	No